Skip to results
Modify your search
NARROW
1-20 of 41048
Image
PI minor drug resistance mutations among adolescents and youths (n ... Get access
Published: 02 May 2025
Figure 2.
PI minor drug resistance mutations among adolescents and youths ( n = 16).
Image
NRTI drug resistance mutations among adolescents and youths (n = 5... Get access
Published: 02 May 2025
Figure 3.
NRTI drug resistance mutations among adolescents and youths ( n = 51).
Image
PI major drug resistance mutations among adolescents and youths (n... Get access
Published: 02 May 2025
Figure 1.
PI major drug resistance mutations among adolescents and youths ( n = 76).
Image
Genotypic susceptibility levels of the PI drugs among adolescents and youth... Get access
Published: 02 May 2025
Figure 4.
Genotypic susceptibility levels of the PI drugs among adolescents and youths with virological failure. ATV/r, ritonavir boosted atazanavir; DRV/r, boosted Darunavir with ritonavir; LPV/r, boosted Lopinavir with ritonavir.
Journal Article
Viral suppression after failure of PI-based ART among adolescents and youths with and without drug resistance mutations: a longitudinal analysis in Tanzania Get access
Journal of Antimicrobial Chemotherapy, dkaf125, https://doi.org/10.1093/jac/dkaf125
Published: 02 May 2025
Image
Probability of PK/PD target attainment for rezafungin 400 mg against C....
Published: 30 April 2025
Figure 4.
Probability of PK/PD target attainment for rezafungin 400 mg against C. auris using CLSI methodology. 79 f AUC 0–168 h , free-drug area under the plasma concentration–time curve from 0 to 168 h; cfu, colony-forming units; CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibit
Journal Article
Activity of rezafungin against Candida auris
Journal of Antimicrobial Chemotherapy, dkaf124, https://doi.org/10.1093/jac/dkaf124
Published: 30 April 2025
Image
(A) Clinical cases of C. auris reported in the USA (2023;...
Published: 30 April 2025
Figure 1.
( A ) Clinical cases of C. auris reported in the USA (2023; n = 4514); 16 ( B ) Case reports of C. auris infection or carriage within countries included in the EU or EEA, excluding the UK (2013–21; n = 1812). 12 AK, Alaska; AL, Alabama; AR, Arkansas; AZ, Arizona; CA, California; CO, Co
Image
Toxicity and survival curves in M. mycetomatis-infected G. mel...
Published: 30 April 2025
Figure 2.
Toxicity and survival curves in M. mycetomatis -infected G. mellonella larvae treated with ibrexafungerp and micafungin. (a) Ibrexafungerp (IBX) was evaluated for toxicity in G. mellonella larvae. Three concentrations, 8 (dark red with dashed line), 2 (bright red with dashed line) and 0.5 (ligh
Image
Survival curves of M. mycetomatis- or F. senegalensis-inf...
Published: 30 April 2025
Figure 3.
Survival curves of M. mycetomatis - or F. senegalensis -infected larvae treated with ibrexafungerp, itraconazole or a combination of both. (a) Survival curves of M. mycetomatis -( M. m ) infected larvae. M. mycetomatis -infected larvae were treated with PBS (black line), 2 mg/kg ibrexafungerp (I
Image
Grains formed in M. mycetomatis- or F. senegalensis-infec...
Published: 30 April 2025
Figure 4.
Grains formed in M. mycetomatis - or F. senegalensis -infected G. mellonella larvae treated with ibrexafungerp, itraconazole, micafungin or the combination of ibrexafungerp and itraconazole. G. mellonella larvae were infected with M. mycetomatis mm55 or F. senegalensis strain CBS197.79 and
Journal Article
Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma
Journal of Antimicrobial Chemotherapy, dkaf133, https://doi.org/10.1093/jac/dkaf133
Published: 30 April 2025
Image
Pharmacokinetics of a 400 mg dose of rezafungin followed by a 200 mg dose o...
Published: 30 April 2025
Figure 2.
Pharmacokinetics of a 400 mg dose of rezafungin followed by a 200 mg dose once-weekly. Figure reproduced from Andes et al. , by permission of Oxford University Press. 50
Image
Efficacy of rezafungin for the treatment of disseminated C. auris ...
Published: 30 April 2025
Figure 3.
Efficacy of rezafungin for the treatment of disseminated C. auris infection in an immunocompromised mouse model: average log cfu/g in kidney tissue over time. cfu, colony-forming units; ip, intraperitoneally; SD, standard deviation. Figure reproduced from Hager et al. , by permission of Oxford Un
Image
Probability of PK/PD target attainment for rezafungin 400 mg against C....
Published: 30 April 2025
Figure 5.
Probability of PK/PD target attainment for rezafungin 400 mg against C. auris using EUCAST E.Def 7.4 methodology with RPMI-1640 assay medium containing 0.002% Tween 20. 80 f AUC 0–168 h , free-drug area under the plasma concentration–time curve from 0 to 168 h; EUCAST, European Committee on A
Image
The MIC values for 37 eumycetoma isolates. Both itraconazole (ITC) and ibre...
Published: 30 April 2025
Figure 1.
The MIC values for 37 eumycetoma isolates. Both itraconazole (ITC) and ibrexafungerp (IBX) were used in susceptibility testing (black for itraconazole and red for ibrexafungerp). The y -axis depicts the number of isolates, and the x -axis depicts the MIC values. MIC values of 37 eumycetoma isol
Image
Grain counts in histology sections prepared from M. mycetomatis- o...
Published: 30 April 2025
Figure 5.
Grain counts in histology sections prepared from M. mycetomatis - or F. senegalensis -infected larvae and treated with PBS, ibrexafungerp, itraconazole, micafungin or the combination of ibrexafungerp and itraconazole. As seen in Figure 4 , grains are stained black by Grocott and can be easily see
Journal Article
A comparative study of the molecular characteristics of human uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019
Journal of Antimicrobial Chemotherapy, dkaf130, https://doi.org/10.1093/jac/dkaf130
Published: 29 April 2025
Image
Core genome phylogeny of 43 E. coli ST 131/8189/CC131 isolated fro...
Published: 29 April 2025
Figure 3.
Core genome phylogeny of 43 E. coli ST 131/8189/CC131 isolated from human urine samples in Norway ( n = 23) and France ( n = 20). Subclades A, B, C1 and C2 are marked. Yellow colours on the tips denote reference genomes for their respective clade: A: GCA_017612165.1; B: GCA_017611745.1; C1: GCA_
Image
Demographic data of patients from whom E. coli were isolated in ur...
Published: 29 April 2025
Figure 1.
Demographic data of patients from whom E. coli were isolated in urine, stratified by age, country, origin and gender.
